Imagine a world without disease. Sounds utopian? AI just made it a multibillion-dollar bet to discover drugs – and forget Big ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

LONDON (Reuters) -Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP on Friday.

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.” The supercomputer, named Gefion ...

Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building a stake in the Ozempic maker.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

Novo Nordisk once held the title of Europe's most valuable company – worth $615 billion at its peak – driven by skyrocketing demand for Wegovy and its diabetes counterpart, Ozempic.